SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
16 déc. 2021 06h00 HE
|
SAB Biotherapeutics, Inc.
FDA laboratory testing confirms SAB-185 neutralizes Omicronand other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue...
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
01 déc. 2021 07h00 HE
|
SAB Biotherapeutics, Inc.
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...
SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update
22 nov. 2021 07h00 HE
|
Sab Biotherapeutics, Inc.
Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis Awarded additional $60.5 million from DoD in expanded...
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
25 oct. 2021 07h40 HE
|
Sab Biotherapeutics, Inc.
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D.,...